4D Molecular Therapeutics, Inc.
FDMT
$4.28
$0.040.94%
| Weiss Ratings | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.95 | |||
| Price History | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.88% | |||
| 30-Day Total Return | -23.57% | |||
| 60-Day Total Return | -34.15% | |||
| 90-Day Total Return | -46.57% | |||
| Year to Date Total Return | -26.59% | |||
| 1-Year Total Return | -85.43% | |||
| 2-Year Total Return | -76.85% | |||
| 3-Year Total Return | -69.10% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -88.19% | |||
| 52-Week Low % Change | 14.87% | |||
| Price | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $36.25 | |||
| 52-Week Low Price | $3.73 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Mar 27, 2024 | |||
| Valuation | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 198.17M | |||
| Enterprise Value | -282.68M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.97 | |||
| Earnings Per Share Growth | 12.36% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7,133.33 | |||
| Price/Book (Q) | 0.38 | |||
| Enterprise Value/Revenue (TTM) | -7,639.99 | |||
| Price | $4.28 | |||
| Enterprise Value/EBITDA (TTM) | 1.54 | |||
| Enterprise Value/EBIT | 1.50 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 55.64M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 510 505 2680 | |||
| Address | 5858 Horton Street EmeryVille, CA 94608 | |||
| Website | www.4dmoleculartherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -507,678.37% | |||
| Profit Margin | -434,778.37% | |||
| Management Effectiveness | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -26.08% | |||
| Return on Equity | -- | |||
| Income Statement | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 37.00K | |||
| Total Revenue (TTM) | 37.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -141.26M | |||
| EBITDA (TTM) | -183.19M | |||
| EBIT (TTM) | -187.84M | |||
| Net Income (TTM) | -160.87M | |||
| Net Income Avl. to Common (TTM) | -160.87M | |||
| Total Revenue Growth (Q YOY) | 105.26% | |||
| Earnings Growth (Q YOY) | -53.86% | |||
| EPS Diluted (TTM) | -2.97 | |||
| EPS Diluted Growth (Q YOY) | -18.54% | |||
| Balance Sheet | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 424.88M | |||
| Cash Per Share (Q) | $7.64 | |||
| Total Current Assets (Q) | 434.93M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 510.61M | |||
| Current Ratio (Q) | 14.921 | |||
| Book Value Per Share (Q) | $11.15 | |||
| Total Assets (Q) | 560.38M | |||
| Total Current Liabilities (Q) | 29.15M | |||
| Total Debt (Q) | 24.61M | |||
| Total Liabilities (Q) | 49.78M | |||
| Total Common Equity (Q) | 510.61M | |||
| Cash Flow | FDMT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -302.44M | |||
| Cash from Financing (TTM) | 337.25M | |||
| Net Change in Cash (TTM) | -99.77M | |||
| Levered Free Cash Flow (TTM) | -82.33M | |||
| Cash from Operations (TTM) | -134.59M | |||
